awmsg logo



defibrotide (Defitelio®)


Reference No. 508

Publication date:
20/05/2015


Appraisal information

defibrotide (Defitelio®) 80 mg/ml concentrate for solution for infusion


Company: Jazz Pharmaceuticals plc
BNF category: Cardiovascular system
NMG meeting date: 25/02/2015
AWMSG meeting date: 25/03/2015
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0515
Ministerial ratification: 15/05/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Defibrotide (Defitelio®) is recommended for use within NHS Wales for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download